|
|
Volumn 117, Issue 3, 2002, Pages 355-357
|
|
The advent of targeted therapeutics and implications for pathologists
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
5 AZA 2' DEOXYCYTIDINE;
6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE;
ABT 839;
ALEMTUZUMAB;
AZACITIDINE;
BUTYRIC ACID;
CGP 77675;
GEFITINIB;
GEMTUZUMAB OZOGAMICIN;
IMATINIB;
LONAFARNIB;
OBLIMERSEN;
RITUXIMAB;
SEMAXANIB;
THALIDOMIDE;
TIPIFARNIB;
TOSITUMOMAB I 131;
TRASTUZUMAB;
TRICHOSTATIN A;
TUMOR VACCINE;
UNCLASSIFIED DRUG;
DRUG EFFECT;
DRUG RESEARCH;
DRUG TARGETING;
EDITORIAL;
HUMAN;
PATHOLOGIST;
PRIORITY JOURNAL;
SIDE EFFECT;
ANTINEOPLASTIC AGENTS;
DRUG DESIGN;
HUMANS;
NEOPLASMS;
PATHOLOGY;
PIPERAZINES;
PROTEIN-TYROSINE KINASES;
PYRIMIDINES;
|
|
EID: 0036126140
PISSN: 00029173
EISSN: None
Source Type: Journal
DOI: 10.1309/JD6G-VRTG-AUK3-WHGC Document Type: Editorial |
|
Times cited : (5)
|
|
References (7)
|
